Many patients with severe asthma who were historically dependent on oral corticosteroids (OCS) for disease control have now entered a new era. Initiation of OCS has become an uncommon event, and many patients with long-standing disease are now able to improve their symptoms and lung function and achieve periods of on-treatment remission, a scenario that was unimaginable only a decade ago. This transformation has been driven by the advent of biologic therapies, which were proven to be both highly effective and safe, thereby facilitating their widespread global adoption.
